{"id":"NCT00389064","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","officialTitle":"A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-10-18","resultsPosted":"2009-06-23","lastUpdate":"2012-04-04"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Disorders"],"interventions":[{"type":"DRUG","name":"Quetiapine XR","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Quetapine XR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.\n\nPLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.","primaryOutcome":{"measure":"Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","timeFrame":"Randomization to Week 9","effectByArm":[{"arm":"Quetiapine XR","deltaMin":-14.97,"sd":7.4},{"arm":"Placebo","deltaMin":-7.21,"sd":7.8}],"pValues":[]},"eligibility":{"minAge":"66 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":43,"countries":["United States","Estonia","Poland","Russia","Ukraine"]},"refs":{"pmids":["23070803"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":223},"commonTop":["Somnolence","Headache","Dry Mouth","Dizziness","Nausea"]}}